Aprea Therapeutics Inc expected to post a loss of $1.50 a share - Earnings Preview

Aprea Therapeutics

12/05/2023 12:16

* Aprea Therapeutics Inc  APRE.OQ   APRE.O  is expected
to show no
change in quarterly revenue when it reports  results on May 15
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Aprea Therapeutics
Inc is
for a loss of $1.50 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 18.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $16​, above​ its last closing price
of $3.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -4.04       -3.08      -0.92     Beat    70.1
 Sep. 30 2022  -9.20       -5.50      -2.40     Beat    56.4
 Jun. 30 2022  -7.00       -7.50      -19.60    Missed  -161.3
                                                        ​
 Mar. 31 2022  -7.60       -7.60      -7.20     Beat    5.3
 ​​Dec.        -8.80       -8.80      -7.20     Beat    18.2
 31 2021                                                
 Sep. 30 2021  -9.04       -9.05      -9.00     Beat    0.6​
 Jun. 30 2021  -9.11       -9.35      -9.60     Missed  -2.7
 Mar. 31 2021  -9.70       -9.85      -9.20     Beat    6.6
 This summary was machine generated May 12 at 11:16 GMT.  All
figures in US dollars  unless otherwise stated